Details
Stereochemistry | ACHIRAL |
Molecular Formula | C12H15N3O2S |
Molecular Weight | 265.331 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCCSC1=CC=C2N=C(NC(=O)OC)NC2=C1
InChI
InChIKey=HXHWSAZORRCQMX-UHFFFAOYSA-N
InChI=1S/C12H15N3O2S/c1-3-6-18-8-4-5-9-10(7-8)14-11(13-9)15-12(16)17-2/h4-5,7H,3,6H2,1-2H3,(H2,13,14,15,16)
Molecular Formula | C12H15N3O2S |
Molecular Weight | 265.331 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionCurator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/11386684
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/11386684
ALBENZA (albendazole) is an orally administered anthelmintic drug. Chemically, it is methyl 5¬ (propylthio)-2-benzimidazolecarbamate, is indicated to treatment of parenchymal neurocysticercosis due to active lesions caused by larval forms of the pork tapeworm, Taenia solium. In addition, treatment of cystic hydatid disease of the liver, lung, and peritoneum, caused by the larval form of the dog tapeworm, Echinococcus granulosus. Albendazole binds to the colchicine-sensitive site of β-tubulin inhibiting their polymerization into microtubules. The decrease in microtubules in the intestinal cells of the parasites decreases their absorptive function, especially the uptake of glucose by the adult and larval forms of the parasites, and depletes glycogen storage. Insufficient glucose results in insufficient energy for the production of adenosine trisphosphate (ATP) and the parasite eventually dies. Albendazole developed in 1975. It is on the World Health Organization's List of Essential Medicines, the most important medications needed in a basic health system. The incidence of side effects reported in the published literature is very low, with only gastrointestinal side effects occurring with an overall frequency of just >1% . Albendazole's unique broad-spectrum activity is exemplified in the overall cure rates calculated from studies employing the recommended doses for hookworm (78% in 68 studies: 92%, for A. duodenale in 23 studies and 75% for N. americanus in 30 studies), A. lumbricoides (95% in 64 studies), T. trichiura (48% in 57 studies), E. vermicularis (98% in 27 studies), S. stercoralis (62% in 19 studies), H. nana (68% in 11 studies), and Taenia spp. (85% in 7 studies).
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/?term=19915628
Curator's Comment: Albendazole penetrates blood–brain barrier, with concentrations in CSF reaching 50% of that found in plasma
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2364705 Sources: https://www.ncbi.nlm.nih.gov/pubmed/11980387 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Curative | ALBENZA Approved UseALBENZA is an anthelmintic drug indicated for: Treatment of parenchymal neurocysticercosis due to active lesions caused by larval forms of the pork tapeworm, Taenia solium. (1.1) Treatment of cystic hydatid disease of the liver, lung, and peritoneum, caused by the larval form of the dog tapeworm, Echinococcus granulosus. (1.2) 1.1 Neurocysticercosis ALBENZA is indicated for the treatment of parenchymal neurocysticercosis due to active lesions caused by larval forms of the pork tapeworm, Taenia solium. 1.2 Hydatid Disease ALBENZA is indicated for the treatment of cystic hydatid disease of the liver, lung, and peritoneum, caused by the larval form of the dog tapeworm, Echinococcus granulosus. Launch Date1996 |
|||
Curative | ALBENZA Approved UseALBENZA is an anthelmintic drug indicated for: Treatment of parenchymal neurocysticercosis due to active lesions caused by larval forms of the pork tapeworm, Taenia solium. (1.1) Treatment of cystic hydatid disease of the liver, lung, and peritoneum, caused by the larval form of the dog tapeworm, Echinococcus granulosus. (1.2) 1.1 Neurocysticercosis ALBENZA is indicated for the treatment of parenchymal neurocysticercosis due to active lesions caused by larval forms of the pork tapeworm, Taenia solium. 1.2 Hydatid Disease ALBENZA is indicated for the treatment of cystic hydatid disease of the liver, lung, and peritoneum, caused by the larval form of the dog tapeworm, Echinococcus granulosus. Launch Date1996 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
39.61 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/12784319 |
800 mg 1 times / day steady-state, oral dose: 800 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
ALBENDAZOLE SULFONE serum | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
1310 ng/mL |
400 mg 2 times / day multiple, oral dose: 400 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
ALBENDAZOLE OXIDE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: FED |
|
707.37 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/12784319 |
800 mg 1 times / day steady-state, oral dose: 800 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
ALBENDAZOLE OXIDE serum | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
284.55 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/12784319 |
800 mg 1 times / day steady-state, oral dose: 800 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
ALBENDAZOLE SULFONE serum | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
3713.96 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/12784319 |
800 mg 1 times / day steady-state, oral dose: 800 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
ALBENDAZOLE OXIDE serum | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
11.91 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/12784319 |
800 mg 1 times / day steady-state, oral dose: 800 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
ALBENDAZOLE SULFONE serum | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
8 h |
400 mg 2 times / day multiple, oral dose: 400 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
ALBENDAZOLE OXIDE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: FED |
|
11.43 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/12784319 |
800 mg 1 times / day steady-state, oral dose: 800 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
ALBENDAZOLE OXIDE serum | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
30% |
400 mg 2 times / day multiple, oral dose: 400 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
ALBENDAZOLE OXIDE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: FED |
Doses
Dose | Population | Adverse events |
---|---|---|
1200 mg 2 times / day multiple, oral MTD Dose: 1200 mg, 2 times / day Route: oral Route: multiple Dose: 1200 mg, 2 times / day Sources: Page: p.600 |
unhealthy, 25–81 n = 9 Health Status: unhealthy Condition: Advanced cancer Age Group: 25–81 Sex: M+F Population Size: 9 Sources: Page: p.600 |
Disc. AE: Neutropenic sepsis... AEs leading to discontinuation/dose reduction: Neutropenic sepsis (grade 5, 11%) Sources: Page: p.600 |
3200 mg 1 times / day multiple, oral Highest studied dose Dose: 3200 mg, 1 times / day Route: oral Route: multiple Dose: 3200 mg, 1 times / day Sources: Page: p.57-58 |
unhealthy, 38 n = 1 Health Status: unhealthy Condition: Neurocysticercosis Age Group: 38 Sex: F Population Size: 1 Sources: Page: p.57-58 |
Disc. AE: Parkinsonism aggravated... AEs leading to discontinuation/dose reduction: Parkinsonism aggravated Sources: Page: p.57-58 |
16 g single, oral (total daily dose) Overdose Dose: 16 g Route: oral Route: single Dose: 16 g Sources: Page: p.10 |
unhealthy n = 1 Health Status: unhealthy Condition: Hydatid Disease Population Size: 1 Sources: Page: p.10 |
|
400 mg 2 times / day multiple, oral Recommended Dose: 400 mg, 2 times / day Route: oral Route: multiple Dose: 400 mg, 2 times / day Sources: Page: p.6 |
unhealthy Health Status: unhealthy Condition: Hydatid Disease|Neurocysticercosis Sources: Page: p.6 |
Disc. AE: Granulocytopenia, Pancytopenia... Other AEs: Bone marrow depression, Aplastic anemia... AEs leading to discontinuation/dose reduction: Granulocytopenia (grade 5) Other AEs:Pancytopenia (grade 5) Bone marrow depression Sources: Page: p.6Aplastic anemia Agranulocytosis Disorder fetal |
400 mg 2 times / day multiple, oral Recommended Dose: 400 mg, 2 times / day Route: oral Route: multiple Dose: 400 mg, 2 times / day Sources: Page: p.9 |
unhealthy Health Status: unhealthy Condition: Hydatid Disease Sources: Page: p.9 |
Disc. AE: Hepatic dysfunction NOS... AEs leading to discontinuation/dose reduction: Hepatic dysfunction NOS (3.8%) Sources: Page: p.9 |
400 mg 2 times / day multiple, oral Recommended Dose: 400 mg, 2 times / day Route: oral Route: multiple Dose: 400 mg, 2 times / day Sources: Page: p.9 |
unhealthy Health Status: unhealthy Condition: Hydatid Disease|Neurocysticercosis Sources: Page: p.9 |
Disc. AE: Leukopenia... AEs leading to discontinuation/dose reduction: Leukopenia (0.7%) Sources: Page: p.9 |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Neutropenic sepsis | grade 5, 11% Disc. AE |
1200 mg 2 times / day multiple, oral MTD Dose: 1200 mg, 2 times / day Route: oral Route: multiple Dose: 1200 mg, 2 times / day Sources: Page: p.600 |
unhealthy, 25–81 n = 9 Health Status: unhealthy Condition: Advanced cancer Age Group: 25–81 Sex: M+F Population Size: 9 Sources: Page: p.600 |
Parkinsonism aggravated | Disc. AE | 3200 mg 1 times / day multiple, oral Highest studied dose Dose: 3200 mg, 1 times / day Route: oral Route: multiple Dose: 3200 mg, 1 times / day Sources: Page: p.57-58 |
unhealthy, 38 n = 1 Health Status: unhealthy Condition: Neurocysticercosis Age Group: 38 Sex: F Population Size: 1 Sources: Page: p.57-58 |
Agranulocytosis | 400 mg 2 times / day multiple, oral Recommended Dose: 400 mg, 2 times / day Route: oral Route: multiple Dose: 400 mg, 2 times / day Sources: Page: p.6 |
unhealthy Health Status: unhealthy Condition: Hydatid Disease|Neurocysticercosis Sources: Page: p.6 |
|
Aplastic anemia | 400 mg 2 times / day multiple, oral Recommended Dose: 400 mg, 2 times / day Route: oral Route: multiple Dose: 400 mg, 2 times / day Sources: Page: p.6 |
unhealthy Health Status: unhealthy Condition: Hydatid Disease|Neurocysticercosis Sources: Page: p.6 |
|
Bone marrow depression | 400 mg 2 times / day multiple, oral Recommended Dose: 400 mg, 2 times / day Route: oral Route: multiple Dose: 400 mg, 2 times / day Sources: Page: p.6 |
unhealthy Health Status: unhealthy Condition: Hydatid Disease|Neurocysticercosis Sources: Page: p.6 |
|
Disorder fetal | 400 mg 2 times / day multiple, oral Recommended Dose: 400 mg, 2 times / day Route: oral Route: multiple Dose: 400 mg, 2 times / day Sources: Page: p.6 |
unhealthy Health Status: unhealthy Condition: Hydatid Disease|Neurocysticercosis Sources: Page: p.6 |
|
Granulocytopenia | grade 5 Disc. AE |
400 mg 2 times / day multiple, oral Recommended Dose: 400 mg, 2 times / day Route: oral Route: multiple Dose: 400 mg, 2 times / day Sources: Page: p.6 |
unhealthy Health Status: unhealthy Condition: Hydatid Disease|Neurocysticercosis Sources: Page: p.6 |
Pancytopenia | grade 5 Disc. AE |
400 mg 2 times / day multiple, oral Recommended Dose: 400 mg, 2 times / day Route: oral Route: multiple Dose: 400 mg, 2 times / day Sources: Page: p.6 |
unhealthy Health Status: unhealthy Condition: Hydatid Disease|Neurocysticercosis Sources: Page: p.6 |
Hepatic dysfunction NOS | 3.8% Disc. AE |
400 mg 2 times / day multiple, oral Recommended Dose: 400 mg, 2 times / day Route: oral Route: multiple Dose: 400 mg, 2 times / day Sources: Page: p.9 |
unhealthy Health Status: unhealthy Condition: Hydatid Disease Sources: Page: p.9 |
Leukopenia | 0.7% Disc. AE |
400 mg 2 times / day multiple, oral Recommended Dose: 400 mg, 2 times / day Route: oral Route: multiple Dose: 400 mg, 2 times / day Sources: Page: p.9 |
unhealthy Health Status: unhealthy Condition: Hydatid Disease|Neurocysticercosis Sources: Page: p.9 |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://pubmed.ncbi.nlm.nih.gov/11901088/ Page: - |
no | |||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/020666Orig1s000rev.pdf#page=183 Page: 183.0 |
yes |
Drug as victim
Tox targets
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://pubmed.ncbi.nlm.nih.gov/28220623/ Page: - |
PubMed
Title | Date | PubMed |
---|---|---|
In-vitro activity of rifabutin and albendazole singly and in combination with other clinically used antimicrobial agents against Pneumocystis carinii. | 1999 Nov |
|
Slow polymerization of Mycobacterium tuberculosis FtsZ. | 2000 Jul |
|
Optimising the benefits of anthelmintic treatment in children. | 2001 |
|
Comparison of worm control strategies in grazing sheep in Denmark. | 2001 |
|
Impact of iron supplementation and deworming on growth performance in preschool Beninese children. | 2001 Apr |
|
In vitro taurocholate-induced segmentation and clustering of Mesocestoides vogae (syn. corti) tetrathyridia (Cestoda)--inhibition byh cestocidal drugs. | 2001 Apr |
|
Comparative metabolism of albendazole and albendazole sulphoxide by different helminth parasites. | 2001 Apr |
|
Subretinal cysticercosis. | 2001 Apr |
|
Echinococcosis of the spleen during pregnancy. | 2001 Apr |
|
Susceptibility of avian hosts to experimental Gymnophalloides seoi infection. | 2001 Apr |
|
A comparative study of different albendazole and mebendazole regimens for the treatment of intestinal infections in school children of Usigu Division, western Kenya. | 2001 Apr |
|
Primary echinococcosis of the sternocleidomastoid muscle. | 2001 Apr |
|
[Disseminated strongyloidiasis]. | 2001 Apr 28 |
|
Microsporidiosis in the graft of a renal transplant recipient. | 2001 Aug |
|
Ivermectin treatment of a traveler who returned from Peru with cutaneous gnathostomiasis. | 2001 Aug 15 |
|
Multispecific resistance of trichostrongyles to benzimidazoles in a goat herd in Germany. | 2001 Feb |
|
[Strongyloides stercoralis infestation in patients with chronic obstructive lung disease in Vega del Segura (Murcia). 3 case reports]. | 2001 Feb |
|
Chemotherapy of enterobiasis (oxyuriasis). | 2001 Feb |
|
Pharmacotherapy of ascariasis. | 2001 Feb |
|
Echinococcus infestation of the splenius capitis. | 2001 Feb |
|
Identification and expression of multidrug resistance-related ABC transporter genes in Candida krusei. | 2001 Feb |
|
Cardiac echinococcosis. | 2001 Feb |
|
Cutaneous larva migrans contracted in England: a reminder. | 2001 Jul |
|
Gnathostomiasis. | 2001 Jul 28 |
|
Efficacy of flubendazole and albendazole against Trichinella spiralis in mice. | 2001 Jun |
|
Improving bioavailability and anthelmintic activity of albendazole by preparing albendazole-cyclodextrin complexes. | 2001 Jun |
|
Treatment of ocular toxocariasis with albendazole. | 2001 Jun |
|
Intestinal helminth infections, anaemia and labour productivity of female tea pluckers in Bangladesh. | 2001 Jun |
|
Seizure recurrence in children with focal seizures and single small enhancing computed tomographic lesions: prognostic factors on long-term follow-up. | 2001 Jun |
|
Late onset temporal lobe epilepsy with MRI evidence of mesial temporal sclerosis following acute neurocysticercosis: case report. | 2001 Jun |
|
Medullary gnathostomiasis in a white patient: use of immunodiagnosis and magnetic resonance imaging. | 2001 Jun 1 |
|
Successful treatment of metronidazole- and albendazole-resistant giardiasis with nitazoxanide in a patient with acquired immunodeficiency syndrome. | 2001 Jun 15 |
|
Development of a new system for prediction of drug absorption that takes into account drug dissolution and pH change in the gastro-intestinal tract. | 2001 Jun 19 |
|
Synthesis and hydrolytic stability studies of albendazole carrier prodrugs. | 2001 Jun 4 |
|
[Response of multiorganic hydatdosis to combined therapy with albendazoleand praziquantel]. | 2001 Mar |
|
Albendazole therapy for solitary persistent cysticercus granuloma. | 2001 Mar |
|
Towards the eradication of hookworm in an isolated Australian community. | 2001 Mar 10 |
|
The effect of different anthelmintic treatment regimens combined with iron supplementation on the nutritional status of schoolchildren in KwaZulu-Natal, South Africa: a randomized controlled trial. | 2001 Mar-Apr |
|
Albendazole therapy and reduced decline in haemoglobin concentration during pregnancy (Sierra Leone). | 2001 Mar-Apr |
|
Albendazole versus placebo in treatment of echinococcosis. | 2001 Mar-Apr |
|
Cystic echinococcosis in semi-nomadic pastoral communities in north-west China. | 2001 Mar-Apr |
|
In vitro effects of albendazole and its metabolites on the cell proliferation kinetics and micronuclei frequency of stimulated human lymphocytes. | 2001 Mar-Apr |
|
Some aspects in the control of schistosomosis and soil-transmitted helminthosis in Yemeni children. | 2001 May |
|
Effect of ruminal microflora on the biotransformation of netobimin, albendazole, albendazole sulfoxide, and albendazole sulfoxide enantiomers in an artificial rumen. | 2001 May |
|
The epidemiology of gastrointestinal nematodes of dairy cattle in central Kenya. | 2001 May |
|
Microsporidial keratoconjunctivitis in a healthy contact lens wearer without human immunodeficiency virus infection. | 2001 May |
|
Gongylonema infection of the mouth in a resident of Cambridge, Massachusetts. | 2001 May 1 |
Patents
Sample Use Guides
Patients weighing 60 kg or greater, 400 mg twice daily; less than 60 kg, 15 mg/kg/day in divided doses twice daily (maximum total daily dose 800 mg). Hydatid disease: 28-day cycle followed by 14-day albendazole-free
interval for a total of 3 cycles.
Neurocysticercosis: 8 to 30 days.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/19846910
The antiproliferative effect of Albendazole (ABZ) on parent PTX-sensitive 1A9 and PTX-resistant sub-line 1A9PTX22 cells (human ovarian cancer)were compared to those induced by colchicine and paclitaxel (PTX). Cells were exposed to drugs for 3 days (colchicine) or 5 days (ABZ and PTX). The results demonstrate the inhibitory effect on 1A9 and 1A9PTX22 cells by ABZ (IC50=237 nM ± 3.65 and 351 nM ± 90 respectively).
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:05:18 GMT 2023
by
admin
on
Fri Dec 15 15:05:18 GMT 2023
|
Record UNII |
F4216019LN
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
FDA ORPHAN DRUG |
94295
Created by
admin on Fri Dec 15 15:05:18 GMT 2023 , Edited by admin on Fri Dec 15 15:05:18 GMT 2023
|
||
|
WHO-ESSENTIAL MEDICINES LIST |
6.1.1
Created by
admin on Fri Dec 15 15:05:18 GMT 2023 , Edited by admin on Fri Dec 15 15:05:18 GMT 2023
|
||
|
CFR |
21 CFR 520.38A
Created by
admin on Fri Dec 15 15:05:18 GMT 2023 , Edited by admin on Fri Dec 15 15:05:18 GMT 2023
|
||
|
WHO-ATC |
P02CA03
Created by
admin on Fri Dec 15 15:05:18 GMT 2023 , Edited by admin on Fri Dec 15 15:05:18 GMT 2023
|
||
|
CFR |
21 CFR 520.38
Created by
admin on Fri Dec 15 15:05:18 GMT 2023 , Edited by admin on Fri Dec 15 15:05:18 GMT 2023
|
||
|
NCI_THESAURUS |
C250
Created by
admin on Fri Dec 15 15:05:18 GMT 2023 , Edited by admin on Fri Dec 15 15:05:18 GMT 2023
|
||
|
WHO-VATC |
QP52AC11
Created by
admin on Fri Dec 15 15:05:18 GMT 2023 , Edited by admin on Fri Dec 15 15:05:18 GMT 2023
|
||
|
CFR |
21 CFR 520.38B
Created by
admin on Fri Dec 15 15:05:18 GMT 2023 , Edited by admin on Fri Dec 15 15:05:18 GMT 2023
|
||
|
CFR |
21 CFR 556.34
Created by
admin on Fri Dec 15 15:05:18 GMT 2023 , Edited by admin on Fri Dec 15 15:05:18 GMT 2023
|
||
|
FDA ORPHAN DRUG |
94195
Created by
admin on Fri Dec 15 15:05:18 GMT 2023 , Edited by admin on Fri Dec 15 15:05:18 GMT 2023
|
||
|
LIVERTOX |
NBK548360
Created by
admin on Fri Dec 15 15:05:18 GMT 2023 , Edited by admin on Fri Dec 15 15:05:18 GMT 2023
|
||
|
NDF-RT |
N0000175481
Created by
admin on Fri Dec 15 15:05:18 GMT 2023 , Edited by admin on Fri Dec 15 15:05:18 GMT 2023
|
||
|
WHO-ESSENTIAL MEDICINES LIST |
6.1.2
Created by
admin on Fri Dec 15 15:05:18 GMT 2023 , Edited by admin on Fri Dec 15 15:05:18 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
F4216019LN
Created by
admin on Fri Dec 15 15:05:18 GMT 2023 , Edited by admin on Fri Dec 15 15:05:18 GMT 2023
|
PRIMARY | |||
|
16664
Created by
admin on Fri Dec 15 15:05:18 GMT 2023 , Edited by admin on Fri Dec 15 15:05:18 GMT 2023
|
PRIMARY | |||
|
F4216019LN
Created by
admin on Fri Dec 15 15:05:18 GMT 2023 , Edited by admin on Fri Dec 15 15:05:18 GMT 2023
|
PRIMARY | |||
|
m1473
Created by
admin on Fri Dec 15 15:05:18 GMT 2023 , Edited by admin on Fri Dec 15 15:05:18 GMT 2023
|
PRIMARY | Merck Index | ||
|
1012553
Created by
admin on Fri Dec 15 15:05:18 GMT 2023 , Edited by admin on Fri Dec 15 15:05:18 GMT 2023
|
PRIMARY | |||
|
220008
Created by
admin on Fri Dec 15 15:05:18 GMT 2023 , Edited by admin on Fri Dec 15 15:05:18 GMT 2023
|
PRIMARY | |||
|
7444
Created by
admin on Fri Dec 15 15:05:18 GMT 2023 , Edited by admin on Fri Dec 15 15:05:18 GMT 2023
|
PRIMARY | |||
|
2082
Created by
admin on Fri Dec 15 15:05:18 GMT 2023 , Edited by admin on Fri Dec 15 15:05:18 GMT 2023
|
PRIMARY | |||
|
430
Created by
admin on Fri Dec 15 15:05:18 GMT 2023 , Edited by admin on Fri Dec 15 15:05:18 GMT 2023
|
PRIMARY | RxNorm | ||
|
DB00518
Created by
admin on Fri Dec 15 15:05:18 GMT 2023 , Edited by admin on Fri Dec 15 15:05:18 GMT 2023
|
PRIMARY | |||
|
100000087712
Created by
admin on Fri Dec 15 15:05:18 GMT 2023 , Edited by admin on Fri Dec 15 15:05:18 GMT 2023
|
PRIMARY | |||
|
54965-21-8
Created by
admin on Fri Dec 15 15:05:18 GMT 2023 , Edited by admin on Fri Dec 15 15:05:18 GMT 2023
|
PRIMARY | |||
|
ALBENDAZOLE
Created by
admin on Fri Dec 15 15:05:18 GMT 2023 , Edited by admin on Fri Dec 15 15:05:18 GMT 2023
|
PRIMARY | |||
|
ALBENDAZOLE
Created by
admin on Fri Dec 15 15:05:18 GMT 2023 , Edited by admin on Fri Dec 15 15:05:18 GMT 2023
|
PRIMARY | Description: A white or almost white powder. Solubility: Practically insoluble in water; soluble in glacial acetic acid R; slightly soluble in acetone R, very slightly soluble in ethanol (~750 g/l) TS. Category: Anthelminthic. Storage: Albendazole should be kept in a well-closed container, protected from light. Additional information: Melting temperature, about 210?C, with decomposition. Requirement: Albendazole contains not less than 98.0% and not more than 101.0% of C12H15N3O2S, calculated with reference to the dried substance. | ||
|
D015766
Created by
admin on Fri Dec 15 15:05:18 GMT 2023 , Edited by admin on Fri Dec 15 15:05:18 GMT 2023
|
PRIMARY | |||
|
N0000191624
Created by
admin on Fri Dec 15 15:05:18 GMT 2023 , Edited by admin on Fri Dec 15 15:05:18 GMT 2023
|
PRIMARY | Cytochrome P450 1A Inducers [MoA] | ||
|
C47384
Created by
admin on Fri Dec 15 15:05:18 GMT 2023 , Edited by admin on Fri Dec 15 15:05:18 GMT 2023
|
PRIMARY | |||
|
3967
Created by
admin on Fri Dec 15 15:05:18 GMT 2023 , Edited by admin on Fri Dec 15 15:05:18 GMT 2023
|
PRIMARY | |||
|
SUB05295MIG
Created by
admin on Fri Dec 15 15:05:18 GMT 2023 , Edited by admin on Fri Dec 15 15:05:18 GMT 2023
|
PRIMARY | |||
|
CHEMBL1483
Created by
admin on Fri Dec 15 15:05:18 GMT 2023 , Edited by admin on Fri Dec 15 15:05:18 GMT 2023
|
PRIMARY | |||
|
albendazole
Created by
admin on Fri Dec 15 15:05:18 GMT 2023 , Edited by admin on Fri Dec 15 15:05:18 GMT 2023
|
PRIMARY | |||
|
103
Created by
admin on Fri Dec 15 15:05:18 GMT 2023 , Edited by admin on Fri Dec 15 15:05:18 GMT 2023
|
PRIMARY | |||
|
DTXSID0022563
Created by
admin on Fri Dec 15 15:05:18 GMT 2023 , Edited by admin on Fri Dec 15 15:05:18 GMT 2023
|
PRIMARY | |||
|
Albendazole
Created by
admin on Fri Dec 15 15:05:18 GMT 2023 , Edited by admin on Fri Dec 15 15:05:18 GMT 2023
|
PRIMARY | |||
|
259-414-7
Created by
admin on Fri Dec 15 15:05:18 GMT 2023 , Edited by admin on Fri Dec 15 15:05:18 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
BINDER->LIGAND |
|
||
|
METABOLIC ENZYME -> SUBSTRATE | |||
|
METABOLIC ENZYME -> SUBSTRATE | |||
|
BINDER->LIGAND |
BINDING
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE INACTIVE -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
METABOLITE -> PARENT |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
sum of impurities B and C: maximum 0.4 percent
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
sum of impurities B and C: maximum 0.4 percent
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Biological Half-life | PHARMACOKINETIC |
|
|
|||